Selank is a synthetic heptapeptide with the amino-acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It was developed from research surrounding tuftsin, an endogenous tetrapeptide with the sequence Thr-Lys-Pro-Arg, with the additional Pro-Gly-Pro sequence creating the seven-amino-acid Selank molecule.
Unlike many peptides studied primarily in metabolic or endocrine research, Selank has attracted scientific interest largely because of its interactions with neurochemical signaling, gene expression, learning and memory models, and stress-related behavioral pathways.
From Tuftsin to Selank
Understanding Selank begins with tuftsin.
Tuftsin is a naturally occurring tetrapeptide associated historically with immune-system research, particularly the activity of phagocytic cells. Its sequence—Thr-Lys-Pro-Arg—forms the first four amino acids of Selank. [1]
Selank extends that structure:
Thr-Lys-Pro-Arg-Pro-Gly-Pro
This places Selank within a broader class of proline- and glycine-containing regulatory peptides sometimes described in the literature as glyprolines. Research has investigated how this structural modification relates to the biological activity of the resulting peptide.
Why Selank Is Studied in Neuroscience
Much of the experimental literature surrounding Selank focuses on the central nervous system.
Researchers have investigated its relationship with several interconnected systems, including GABAergic neurotransmission, serotonergic signaling, noradrenergic signaling, enkephalin metabolism, gene-expression pathways, and neurotrophic signaling.
Importantly, these represent research pathways rather than a single established mechanism explaining every reported experimental observation. That distinction matters because regulatory peptides can interact with biological systems at several levels simultaneously.
Selank and GABAergic Signaling
One particularly interesting area involves the GABAergic system.
GABA, or gamma-aminobutyric acid, is a major inhibitory neurotransmitter in the nervous system. Researchers have examined whether Selank influences components involved in GABA signaling.
A 2016 study reported changes in the expression of certain genes involved in GABAergic neurotransmission following Selank administration in an experimental model. [3]
The broader mechanistic picture remains complex, which makes Selank a useful example of why peptide research rarely reduces to a single pathway.
Enkephalins and Peptide Metabolism
Another research direction involves enkephalins, endogenous peptides involved in neurological signaling.
Laboratory studies have found that Selank can inhibit enzymes involved in enkephalin degradation. In one investigation, Selank inhibited enzymatic hydrolysis of plasma enkephalin in a concentration-dependent manner. [2]
This has led researchers to investigate whether part of Selank's biological activity could arise indirectly by influencing the breakdown and persistence of other regulatory peptides rather than acting exclusively through one conventional receptor target.
Gene Expression and the Hippocampus
Selank research has also extended into transcriptomics—the study of changes in gene expression.
Experimental work examining hippocampal tissue has reported changes in gene-expression profiles following Selank exposure. [6]
These findings are interesting from a research standpoint because they suggest that peptide signaling can potentially produce downstream molecular effects considerably broader than the initial peptide-target interaction.
Learning and Memory Research
Selank has consequently been investigated in experimental models involving learning, memory, attention, and cognitive processing.
Animal research has examined relationships between Selank, monoamine metabolism, and behavioral measures associated with learning and memory. These studies provide research hypotheses and mechanistic clues, but animal-model findings should not automatically be interpreted as demonstrating equivalent outcomes in humans.
Selank and BDNF Research
Another research area involves brain-derived neurotrophic factor (BDNF).
BDNF is a signaling protein involved in neuronal development, synaptic plasticity, and processes associated with learning and memory.
A 2019 rat study examined Selank in an experimental model involving chronic ethanol exposure and reported changes associated with memory-related behavioral measures and BDNF concentrations in the hippocampus and prefrontal cortex. [4]
The significance is not that Selank can simply be described as a “BDNF peptide.” Rather, this work adds neurotrophic signaling to the collection of pathways being investigated as researchers try to understand its broader biological activity.
A Multi-Pathway Research Picture
Taken together, the Selank literature illustrates something important about regulatory-peptide research.
The molecule is being investigated across several overlapping biological systems rather than through one universally established mechanism.
GABAergic signaling → enkephalin metabolism → monoamine signaling → gene expression → neurotrophic pathways → learning and memory models.
Those pathways can influence one another, making it difficult to attribute every experimental observation to one molecular interaction. That complexity is part of what makes Selank scientifically interesting.
Technical Identity
Common name: Selank
Peptide length: 7 amino acids
Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro
One-letter sequence: TKPRPGP
Classification: Synthetic regulatory heptapeptide / tuftsin analogue
Selank is commonly characterized in the scientific literature as a synthetic analogue derived from the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro extension.
Specific identity, purity, analytical characteristics, and lot-specific specifications for an individual research material should be determined from the corresponding analytical documentation rather than inferred solely from the commonly recognized identity of Selank.
Why Selank Remains an Interesting Research Peptide
Selank provides a useful case study in how a relatively small peptide can be investigated across multiple levels of biological organization.
Researchers have studied interactions involving peptide-degrading enzymes, neurotransmitter systems, receptor-associated processes, gene-expression changes, neurotrophic signaling, and behavioral models.
The literature does not establish that all of these observations arise from one mechanism—and that is precisely why continued mechanistic research is valuable.
For researchers, Selank represents an interesting intersection between peptide chemistry, molecular signaling, neuroscience, and regulatory-peptide biology.
Explore Selank at Azyven Research
For researchers interested in Selank as a laboratory research material, view the available product specifications and analytical documentation on the Azyven Research Selank product page →
Azyven Research materials are supplied strictly for laboratory research and analytical purposes. Not for human or veterinary use.
References & Further Reading
1. Fridkin M, Najjar VA. Tuftsin: its chemistry, biology, and clinical potential. Crit Rev Biochem Mol Biol. 1989;24(1):1–40. DOI: 10.3109/10409238909082550. PMID: 2667894.
2. Zozulya AA, Kost NV, Sokolov OYu, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001;131(4):315–317. DOI: 10.1023/A:1017979514274. PMID: 11550013.
3. Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. DOI: 10.3389/fphar.2016.00031. PMID: 26924987.
4. Kolik LG, Nadorova AV, Antipova TA, et al. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bull Exp Biol Med. 2019;167(5):641–644. DOI: 10.1007/s10517-019-04588-9. PMID: 31625062.
5. Rogozinskaya EYa, Lyapina MG. Anticoagulant Effects of Arginine-Containing Peptides of the Glyproline Family. Bull Exp Biol Med. 2017;164(2):170–172. DOI: 10.1007/s10517-017-3950-4. PMID: 29181670.
6. Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank. PMID: 24450168.